Treating atopic dermatitis with ceramide hyaluronic acid emollient foam

Treating atopic dermatitis: safety, efficacy, and patient acceptability of a ceramide hyaluronic acid emollient foam.

Article specifications

This review study was published in 2012 in Journal of Clin Cosmet Investig Dermatol. (IF 2015:3.26) by American specialists. By comparison, review of the profile of ceramide-containing emollients recently has shown these agents to be extremely safe. Furthermore, calcineurin inhibitors are FDA approved for the treatment of children 2 years of age and older. Topical ceramide emollient foams offer cutaneous barrier improvement, are remarkably safe, and are approved for use even in young children.

 

Results

As cost may impact compliance and indirectly, efficacy, newer prescription devices like Hylatopic, which are expensive, must be evaluated with respect to cost versus benefit. The use of traditional emollients and topical steroids is effective in the majority of patients suffering from AD and these agents can be employed safely and inexpensively. The addition of topical calcineurin inhibitors is a safe and effective therapy or these agents may serve as augmentation to treatment. Further understanding of the pathophysiology of AD has resulted in new, effective, and safe treatment in those patients who have failed other regimens or refuse to use those modalities to effectively control the underlying skin disease.